Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
True North Therapeutics
Biotech
Electra aims to light up Nasdaq with IPO for phase 2/3 I&I push
The 2026 IPO streak continues as Electra Therapeutics has filed to go public to support its immunology and cancer pipeline.
Will Maddox
Aug 31, 2026 11:27am
Reach for the Star: Electra nabs $84M for rare disease drugs
Feb 16, 2022 7:00am
Bioverativ, Bicycle sign $424M-plus blood disease R&D pact
Sep 6, 2017 6:50am
Bioverativ to buy True North for $400M upfront
May 23, 2017 9:06am
True North raises $45M in Series D toward rare drug trials
Oct 18, 2016 7:00am
